Effect of fluvastatin and bezafibrate combination on plasma levels of fibrinogen, t-plasminogen activator, PAI-1 and C reactive protein in coronary artery disease patients with combined hyperlipidemia (fact study)

SummaryWe studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemiaIn this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks.Plasma fibrinogen significantly decreased after treatment with the combinations fluvastatin+bezafibrate (−14 and −16%) and with bezafibrate monotherapy (−9%). No significant reduction was observed after fluvastatin monotherapy (−4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C.The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.

Download Full-text

Short term effect of atorvastatin on plasma levels of MCP-1, ICAM-1 and C-reactive protein in patients with coronary artery disease

Atherosclerosis ◽

10.1016/s0021-9150(00)80209-9 ◽

2000 ◽

Vol 151 (1) ◽

pp. 46

Author(s):

A Figueredo ◽

L Reinares ◽

A Rueda ◽

A Rodriguez ◽

M Ruiz-Yagüe ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasma Levels ◽

Term Effect ◽

C Reactive Protein ◽

Short Term ◽

Short Term Effect ◽

Reactive Protein ◽

Artery Disease

Download Full-text

THE PROGNOSIS SIGNIFICANCE OF BLOOD PLASMA LEVELS OF HIGH SENSITIVITY C-REACTIVE PROTEIN AND THE SYSTEM OF CYTOKINES FOR THE ASSESSMENT OF RISK OF ATRIAL FIBRILLATION DEVELOPING IN PATIENTS WITH ARTERIAL HYPERTENSION, CORONARY ARTERY DISEASE AND HF

Bulletin of Problems Biology and Medicine ◽

10.29254/2077-4214-2019-1-2-149-215-220 ◽

2019 ◽

Vol 1 (2) ◽

pp. 215

Author(s):

M. I. Yalovenko ◽

O. O. Khaniukov

Keyword(s):

Atrial Fibrillation ◽

Coronary Artery Disease ◽

Coronary Artery ◽

Arterial Hypertension ◽

Blood Plasma ◽

Plasma Levels ◽

High Sensitivity ◽

C Reactive Protein ◽

Reactive Protein ◽

Artery Disease

Download Full-text

Elevated Plasma Levels of B-Type Natriuretic Peptide but Not C-Reactive Protein Are Associated With Higher Red Cell Distribution Width in Patients With Coronary Artery Disease

International Heart Journal ◽

10.1536/ihj.50.301 ◽

2009 ◽

Vol 50 (3) ◽

pp. 301-312 ◽

Cited By ~ 59

Author(s):

Hidekatsu Fukuta ◽

Nobuyuki Ohte ◽

Seiji Mukai ◽

Tomoaki Saeki ◽

Kaoru Asada ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasma Levels ◽

Red Cell ◽

Cell Distribution ◽

Elevated Plasma ◽

C Reactive Protein ◽

Distribution Width ◽

Reactive Protein ◽

Artery Disease

Download Full-text

Impaired Fibrinolysis in Angiographically Documented Coronary Artery Disease

Advances in Hematology ◽

10.1155/2015/214680 ◽

2015 ◽

Vol 2015 ◽

pp. 1-5 ◽

Cited By ~ 3

Author(s):

Adriano Basques Fernandes ◽

Luciana Moreira Lima ◽

Marinez Oliveira Sousa ◽

Vicente de Paulo Coelho Toledo ◽

Rashid Saeed Kazmi ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasminogen Activator ◽

Plasma Levels ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Fibrinolysis Inhibitor ◽

Artery Disease ◽

Stable Cad ◽

Pai 1

Impaired fibrinolysis may predispose to coronary artery disease (CAD). Hypofibrinolysis due to high levels of plasminogen activator inhibitor-1 (PAI-1) has been reported in CAD. A novel regulator of fibrinolytic activity, thrombin activatable fibrinolysis inhibitor (TAFI), has attracted attention in recent years. It acts by blocking the formation of a ternary complex of plasminogen, fibrin, and tissue plasminogen activator (t-PA). Previously ambiguous results regarding TAFI levels have been reported in CAD. We measured plasma levels of PAI-1 and TAFI antigen in 123 patients with age ranging from 40 to 65 years who had been submitted to coronary angiography and assessed the association of these markers with the extent of stenosis in three groups: angiographically normal artery (NAn), mild to moderate atheromatosis (MA), and severe atheromatosis (SA). Plasma levels of PAI-1 were increased in patients with severe atheromatosis compared to mild/moderate atheromatosis or to normal patients (66.60, 40.50, and 34.90 ng/mL, resp.;P< 0.001). For TAFI no difference was found between different groups. When patients were grouped in only two groups based on clinical cut-off point for intervention (stenosis less than or above 70%) we found increased plasma levels for PAI-1 (37.55 and 66.60 ng/mL, resp.;P< 0.001) and decreased plasma levels for TAFI (5.20 and 4.53 μg/mL, resp.;P= 0.04) in patients with stenosis above 70%. No difference was found in PAI-1 or TAFI levels comparing the number of affected vessels.Conclusion. As evidenced by a raised level of PAI-1 antigen, one can suggest an impaired fibrinolysis in stable CAD, although no correlation with the number of affected vessels was found. Curiously, a decreased plasma level of total TAFI levels was observed in patients with stenosis above 70%. Further studies measuring functional TAFI are required in order to elucidate its association with the extent of degree of atheromatosis.

Download Full-text

Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-Plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study) – A Rebuttal

Thrombosis and Haemostasis ◽

10.1055/s-0037-1612931 ◽

2001 ◽

Vol 85 (01) ◽

pp. 189-189 ◽

Cited By ~ 2

Author(s):

Gideon Hirschfield

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Plasma Fibrinogen ◽

C Reactive Protein ◽

Protein Levels ◽

Reactive Protein ◽

Artery Disease ◽

Activator Inhibitor

Download Full-text

Fibrinolytic Response to Venous Occlusion Compared to Physical Stress Test in Young Patients with Coronary Artery Disease

Thrombosis and Haemostasis ◽

10.1055/s-0037-1615560 ◽

1999 ◽

Vol 82 (S 01) ◽

pp. 80-84 ◽

Cited By ~ 1

Author(s):

Senta Graf ◽

Renate Beckmann ◽

Stephan Hornykewycz ◽

Jeanette Koller-Strametz ◽

Bernd R. Binder ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasminogen Activator ◽

Plasma Levels ◽

Stress Test ◽

Study Groups ◽

Venous Occlusion ◽

Fibrinolytic System ◽

Artery Disease ◽

Pai 1

Summary Introduction: Venous occlusion (VO) and exercise stress (ES) are stimulators of the fibrinolytic system. Aim of this study was to answer which of both stimulation tests is more useful in patients with symptom-limited coronary artery disease (CAD) to evaluate possible defects in the fibrinolytic system. Methods and results: We investigated 20 patients (M/F = 15/5; mean age = 36.7 years) with angiographically proven CAD for their plasma levels of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-type-1 (PAI-1) at basal conditions as well as after VO and at maximal ES (standardised bicycle stress test) and compared the data to those obtained from 12 sex- and age-matched healthy controls (M/F = 9/3; mean age = 40.4 years). At basal conditions mean t-PA activity and t-PA antigen plasma levels were within the normal range and comparable between the two study groups. After both VO and maximal ES, mean t-PA activity and t-PA antigen levels increased significantly more in the control group as compared to the CAD group. Mean PAI-1 activity plasma levels were significantly higher in the CAD group at basal conditions before VO (patients 7.0 ± 3.1; controls 3.9 ± 3.9; IU/ml; p = 0.025) as well as before ES (patients 8.1 ± 3.5; controls 4.3 ± 3.8; IU/ml; p = 0.009). PAI-1 activity plasma levels showed a significant decrease for patients and controls only after VO, while PAI-1 activity was not significantly decreased in both study groups at maximal ES. Discussion: The significantly higher increase in mean plasma levels of t-PA activity and t-PA antigen after VO compared to ES in both groups might be explained by the fact that CAD induced symptoms in the patients during ES thus permitting only 80% of their age, sex, and body mass index related optimal work load. Conclusion: VO and ES are applicable triggers of the endogenous fibrinolytic system in healthy subjects and patients who are not limited in their physical exercise. Standardised VO appears to be superior to ES as stimulation test of the endogenous fibrinolytic system in patients with symptomatic CAD.

Download Full-text